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A B S T R A C T
We aim to find a link between keratokonus (KC) and bullous keratopathy (BK), and extra cellular matrix re-modella-
tion molecules. The activities of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), pro-matrix
metalloproteinase-13 (proMMP-13) and tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) were measured using
immunoassay in three human corneal tissue layers (epithelium, stroma and endothelium) supernatants of the patients
with KC and BK which underwent the perforative keratoplasty. MPP-2, MMP-9, proMMP-13 and TIMP-1 activity was
detected in all samples. The epithelial layer showed significantly higher levels of MMP-9 and proMMP-13 in BK than in
KC. Increased levels of MMP-2 (p=0.07) levels were found in bullous keratopathy compared to keratoconus patients. Epi-
thelial TIMP-1 showed no significant difference in activity between KC and BK. All these findings suggest an active deg-
radation of the extra-cellular matrix in epithelial corneal layer in Bullous Keratopathy. No difference in the concentra-
tion of MMP-2, MMP-9, proMMP-13 and TIMP-1 between KC and BK in corneal stroma and endothelium suggest that
neither of these molecules play important role in KC or BK pathogenesis, at least not in stroma and endothelium.
Key words: corneal transplantation, keratoconus, corneal edema, metalloproteinases, tissue inhibitor of metallo-
proteinase-1
Introduction
Keratoconus (KC) and bullous keratopathy (BK) are
one of the leading indications for corneal transplantation
in the past few years1–5. Keratoplasty (or corneal tans-
plantation; grafting) is a procedure in which an abnor-
mal corneal tissue is replaced by a healthy donor cornea.
There are full-thickness (penetrating) and partial-thick-
ness (lamellar or deep lamellar) grafting techniques.
Keratoplasty can be performed for optical, tectonical,
therapeutic and cosmetic reasons. Corneal transplanta-
tion is a very successful procedure but not without com-
plications. It seems that early detection and effective pre-
vention of KC and BK could be the best solution but since
all the details in the pathogenesis of both BK and KC are
not known these patients still undergo corneal trans-
plantation. Tissue-remodeling-involved enzymes seem to
have an important role in the pathogenesis of KC and
BK6, thus measuring their activity levels in the corneal
tissue could help us to better understand these diseases
and it may finally enable us to develop more efficient
treatment options to postpone or avoid corneal trans-
plantation. In this study we measured the activity levels
of matrix metalloproteinase-2 (MMP-2), matrix metallo-
proteinase-9 (MMP-9), pro-matrix metalloproteinase-13
(proMMP-13) and tissue inhibitor of matrix metallo-
proteinases-1 (TIMP-1) 1 in different corenal layers (epi-
thelium, stroma, endothelium) and evaluated the ob-
tained differences between BK and KC affected eyes.
Bullous keratopathy (BK)
BK is characterized by chronic corneal stromal ede-
ma, with or without sub epithelial bullae resulting from
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corneal endothelial disease. Most frequently it is due to
Fuchs’ corneal endothelial dystrophy or corneal endothe-
lial trauma but it is can occur also iatrogenic, usually
caused by cataract extraction with intraocular lens im-
plantation. As a result of the stromal and epithelial
edema, Bowman’s layer and the epithelial basement
membrane attenuate or rupture, leading to poor epithe-
lial adhesion and formation of sub epithelial bullae that
continuously rupture, resulting in recurrent erosions
and persistent epithelial defects, exposing the cornea at
times to infectious ulcers. A vicious cycle of wound for-
mation and wound healing results in a state of chronic
inflammation. In severe cases corneal transplantation is
needed, but usually it is not as successful as in KC.
Keratoconus (KC)
Keratoconus is a progressive disorder characterized
by corneal thinning and assuming irregular conical shape
which induces serious distortion of visual images. Histo-
logical analysis displays typical Bowman layer breaks
and sub epithelial fibrosis with deposition of various ex-
tra cellular matrix (ECM) components. At least 1 of 2000
persons is affected7,8. Keratoconus affects young individ-
uals in their late teens or early twenties with variable
progression thereafter. The disease usually slowly pro-
gresses for 10 to 20 years as the cornea steepens and
scars9. Although both eyes may be affected, one eye is
usually worse than the other. There is no universal the-
ory on pathogenesis of keratoconus. Eran P. et al. found a
genetic disorder with variable expression among the car-
riers in Ashkenazi Jewish family10. Low or negligible lev-
els of alpha-enolase in the epithelial cells of keratoconus
corneas compared to normal corneas were found and at-
tributed to relatively greater degradation of the two pro-
teins in keratoconus corneas compared to normal cor-
neas in two different studies11,12. Decreased levels of lysyl
oxidase, enzyme responsible for collagen cross linking,
was reported in keratoconus corneas13. Keratoconus pro-
gression in hypothyroxinaemia during pregnancy was
also reported indicating hormonal involvement14. We do
not know any successful treatment to prevent progres-
sion of keratoconus. Visual disorders in mild cases of
keratoconus can be successfully treated with glasses or
specially designed contact lenses15. When vision is no lon-
ger satisfactory with glasses or contact lenses, a corneal
transplantation may be recommended.
Matrix metalloproteinases (MMP)
The extra cellular matrix (ECM) which represents the
majority of corneal tissue not only gives stability and
maintains the shape of a cornea but also has a great re-
sponsibility for maintaining visual transparency of the
corneal tissue. Group of enzymes having important role
in the very complex process of ECM degradation are a
super-family of Zink-dependent enzymes called matrix
metalloproteinases (MMP). Nowadays more than 20 MMP
types are described in humans and on the basis of sub-
strate specificity, sequence similarity, and domain organi-
zation; they are divided into six groups: collagenases,
stromelisins, gelatinases, matrilysins, membrane type
MMP (MT-MMP) and other MMP types16. Different cell
types are involved in producing MMP, but predominantly
connective tissue cells and immunological cells. Under
normal physiological conditions, as far as we know, the
activities of MMPs are precisely regulated at the level of
transcription, activation of the precursor zymogens, in-
teraction with specific ECM components and inhibition
by endogenous inhibitors16–18. MMPs can be activated by
proteinases or in vitro by chemical agents.
Matrix metalloproteinase-13 (MMP-13), also known
as collagenase III, is secreted collagenase that plays a
physiological role in the degradation of extra cellular ma-
trix found in skeletal tissues. Ye and al.19 suggested that
MMP-13 may play an important role in the MMP-9-asso-
ciated proteolytic cascade that allows rapid turnover of
the ECM components during corneal wound healing.
Matrix metalloproteinase-2 (MMP-2), also known as
Gelatinase A, is secreted as proMMP-2 which is not
readily activated by general proteinases. The main acti-
vation of proMMP-2 takes place on the cell surface and is
mediated by MT-MMPs. MMP-2 is also activated by MMP-1
and MMP-1316. Gelatinases (MMP-2 and MMP-9) de-
grade denatured collagen, gelatin, native type IV, V and
VII collagens as well as other ECM components16,20–22.
MMP-2 also digests fibrillar type I and II collagens23.
Matrix metalloproteinase-9 (MMP-9), also known as
Gelatinase B, is secreted as proMMP-9, activated by
plasmin, MMP-3, MMP-13 and MMP-26. Transforming
growth factor b (TGFb), tumor necrosis factor a (TNF-a),
interleukin-1b (IL-1b), lipopolysaccharide (LPS) and en-
dothelial growth factor (EGF) are known as inducers of
the MMP-9. Higher levels of MMP-9 have been found in
the corneal epithelium of the patients with pseudophakic
corneal edema24.
Tissue inhibitors of matrix metalloproteinases
(TIMP)
Tissue Inhibitors of MMPs (TIMP) are multifunctio-
nal mollecules involved in specific reversible inhibition of
MMP activity but also have other roles in cell cyclus18,25.
They bind MMPs in a 1:1 stoichiometry so changes of
TIMP levels directly affect the level of MMP activity.
Four TIMPs (TIMP-1, TIMP-2, TIMP-3, and TIMP-4)
have been identified in vertebrates26. Their expressions
vary during development and tissue remodeling.
Materials and Methods
Corneal tissue buttons collected after penetrating ke-
ratoplasty of fourteen consecutive patients (eyes) with
bullous keratopathy (7 patients) and keratoconus (7 pa-
tients) were micro surgically divided into three layers:
epithelium, stroma and endothelium with Descemet mem-
brane. Pachymetry and diameter of each tissue sample
were measured and tissue volume calculated. Tissue
samples were separately incubated in 0.5 milliliters of
tissue culture (Cornea Prep® solution, Eurobio, France)
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for 24 hours at 37 °C and after stored at –80 °C for fur-
ther examination.
Immediately after defrosting, the levels of activity of
matrix metalloproteinase-2 (MMP-2), matrix metallopro-
teinase-9 (MMP-9), pro- matrix metalloproteinase-13 (pro-
-MMP-13) and tissue inhibitor of matrix metalloproteina-
ses-1 (TIMP-1) were measured in tissue sample superna-
tants by enzyme linked immunosorbent assay (ELISA,
Quantikine®, R&D Systems Inc).
The data were analyzed using statistical package »Sta-
tgrasphics plus 4.0 for Windows«. The data was pre-
sented as mean ± sem (standard error of mean). The sig-
nificance difference of compared samples was determined
using student t-test.
Results
MMP-2, MMP-9, pro MMP-13 and TIMP-1 activity in
all three corneal layers of the corneal tissue supernatant
samples both for bullous keratopathy (Table 1) and ke-
ratoconus (Table 2) were measured.
Epithelial tissue supernatants showed significantly
higher concentration of MMP-9 in BK (35.12±9.23 ng/
mL) than in KC (5.31±3.45 ng/mL, n=7) (p =0.010, Fig-
ure 1). Epithelial tissue supernatants also showed signi-
ficantly higher concentration of proMMP-13 in BK
(301.73±75.81 pg/mL, n=6) than in KC (90.69±30.61
pg/mL, n=6) (p = 0.027, Figure 2).
MMP-2 concentration in epithelial layer was much
higher (7.02±3.08, n=6) in BK patients than in KC pa-
tients (1.44±0.50 (n=6) (p=0.078, Figure 3). TIMP-1 con-
centration in epithelial tissue supernatants showed in-
creased, but not significant, levels in BK as compared to
KC (Tables 1, 2).
Stromal and endothelial layer tissue supernatants
showed no significant difference in MMP-2, MMP-9,
proMMP-13 and TIMP-1 concentration between BK and
KC (Tables 1, 2).
Discussion
Several surgical techniques of corneal transplanta-
tion are nowadays reasonable, but far from ideal, therapy
for treating patients with keratoconus and bullous kera-
topathy. Better understanding of the pathogenesis of
these diseases would allow us to predict and on time ef-
fectively prevent or even cure affected patients. MMPs
may be one of the factors involved in the pathogenesis of
mentioned diseases. In this study we have found that the
corneal epithelial concentrations of MMP-9 and proMMP-
-13 are significantly higher in BK than in KC; that
MMP-2 epithelial concentration is also higher in BK than
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TABLE 1
AVERAGE MMP-2, MMP-9, PROMMP-13 AND TIMP-1
CONCENTRATION IN HUMAN CORNEAL EPITHELIUM, STROMA AND ENDOTHELIUM LAYERS IN BULLOUS KERATOPATHY
MMP-2 (ng/mL) MMP-9 (ng/mL) proMMP-13 (pg/mL) TIMP-1 (ng/mL)
Epithelium 7.02 ± 3.08 (n=6) 35.21 ± 9.23 (n=7) 301.73 ± 75.81 (n=6) 0.60 ± 0.24 (n=7)
Stroma 55.72 ± 13.50 (n=7) 1.82 ± 0.47 (n=7) 406.78 ± 244.10 (n=7) 15.06 ± 2.78 (n=7)
Endothelium 4.27 ± 2.27 (n=7) 1.07 ± 0.22 (n=7) 195.79 ± 105.58 (n=7) 0.80 ± 0.25 (n=7)
MMP-2 – matrix metalloproteinase-2, MMP-9 – Matrixmetalloproteinase-9, proMMP-13 – pro matrix metalloproteinase-13,
TIMP-1 – tissue inhibitor of matrix metalloproteinases-1
TABLE 2
AVERAGE MMP-2, MMP-9, PROMMP-13 AND TIMP-1 CONCENTRATION IN HUMAN CORNEAL EPITHELIUM,
STROMA AND ENDOTHELIUM LAYERS IN KERATOCONUS
MMP-2 (ng/mL) MMP-9 (ng/mL) proMMP-13 (pg/mL) TIMP-1 (ng/mL)
Epithelium 1.44 ± 0.50 (n=6) 5.31 ± 3.45 (n=7) 90.69 ± 30.61 (n=6) 1.28 ± 1.00 (n=7)
Stroma 63.26 ± 3.66 (n=7) 2.02 ± 0.88 (n=7) 156.34 ± 42.85 (n=7) 15.58 ± 3.04 (n=7)
Endothelium 12.99 ± 3.43 (n=7) 1.00 ± 0.14 (n=7) 81.53 ± 23.79 (n=7) 2.67 ± 1.50 (n=7)
MMP-2 – matrix metalloproteinase-2, MMP-9 – Matrixmetalloproteinase-9, proMMP-13 – pro matrix metalloproteinase-13,





















Fig. 1. Average concentrations of MMP-9 in corneal epithelial tis-
sue supernatants in Bullous Keratopathy and Keratoconus
(p=0.010).
in KC (yet not significantly, p=0.07) and that there was
no difference in TIMP-1 epithelial concentration between
KC and BK.
MMP-9, the level of which we have proved to be in-
creased in BK, cleaves mostly collagen types IV and
V23,27. This finding could partially explain bullous cha-
nges and recurrent erosions in BK, since collagen IV
which forms epithelial basal lamina, is cleaved by MMP-9.
The higher concentration of MMP-9 in bullous kerato-
pathy is contributed by increased levels of NO in edema-
tous (thus hypoxic) corneal tissue28 and increased levels
of pro-inflammatory cytokines like TGFb, TNF-a, IL-1b,
LPS and EGF as known inducers of the MMP-9. In-
creased MMP-9 levels, with hypoxia could be also respon-
sible for increasing VEGF levels and new blood vessels
ingrowth29 in BK. Our results further suggest that we
could slow down or even stop formation of bullae, ero-
sions and new vessels in BK and postpone keratoplasty,
by stopping the activity of MMP-9.
In corneal stroma and endothelium we haven’t found
any significant difference in expression of MMP-2, MMP-9,
proMMP-13 and TIMP-1 between BK and KC. When
compared to findings in epithelium, this finding implies
that in BK extracellular matrix degradation is the most
intense in corneal epithelial layer and that MMP-2, MMP-
-9, proMMP-13 and TIMP-1 play a minor role in the
pathogenesis of both diseases, at least in stromal and en-
dothelial layer.
Mackiewicz et al. found increased levels of MMP-13 in
keratoconus corneas6 and our findings suggest not nor-
mal (at least not increased) concentration of proMMP-13
in KC which implies that MMP-13 proteinase inhibi-
tor/activator cascade may be affected in keratoconus.
Conclusion
Higher MMP-2 and significantly higher activity levels
of MMP-9 and proMMP-13 were found in human corneal
epithelial layers in patients with bullous keratopathy
than in keratoconus patients. These findings indicate
that there is an active degradation of the extracellular
matrix in epithelial corneal layer in bullous keratopathy.
No MMP-2, MMP-9, proMMP-13 and TIMP-1 difference
in concentration between KC and BK in corneal stroma
and endothelium suggest that neither of these molecules
play important role in KC or BK pathogenesis, at least
not in stroma and endothelium.
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Fig. 2. Average concentrations of proMMP-13 in corneal epithelial





















Fig. 3. Average concentrations of MMP-2 in corneal epithelial tis-
sue supernatants in Bullous Keratopathy and Keratoconus
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EKSPRESIJA MMP-2, MMP-9, PROMMP-13 I TIMP-1 KOD BULOZNE
KERATOPATIJE I KERATOKONUSA
S A @ E T A K
Keratokonus (KC) i Bulozna keratopatija (BK) uzrokuju zna~ajne vidne smetnje i me|u naj~e{}im su indikacijama
za transplantaciju ro`nice u Hrvatskoj i u svijetu u zadnjih nekoliko godina. Na{ je cilj u ovom radu prona}i vezu
izme|u ovih poreme}aja i enzima koji sudjeluju u pregradnji izvanstani~ne tvari, matrix metalloproteinaza (MMP).
Aktivnost matrix metaloproteinaze-2 (MMP-2), matrix metaloproteinaze-9 (MMP-9), pro-matrix metaloproteinaze-13
(proMMP-13) i tkivnog inhibitora matrix metaloproteinaza-1 (TIMP-1) mjerene su metodom enzyme linked immuno-
sorbent assay (ELISA) u supernatantima tri sloja ro`nice (epitel, stroma, endotel) pacijenata oboljelih od KC i BK koji
su prethodno podvrgnuti perforativnoj keratoplastici. Aktivnost MPP-2, MMP-9, proMMP-13 i TIMP-1 je detektirana u
svim promatranim uzorcima. Za razliku od TIMP-1 gdje nije uo~ena razlika, koncentracija MMP-9 i proMMP-13 u
ro`ni~nom epitelu je bila statisti~ki zna~ajno vi{a u pacijenata oboljelih od BK, nego u onih oboljelih od KC. Povi{ene
koncentracije MMP-2 (p=0,07) tako|er su zabilje`ene u ro`ni~nom epitelu pacijenata oboljelih od BK, nego u onih
oboljelih od KC. Sve ovo upu}uje da je degradacija epitelnog ekstracelularnog matriksa kod bulozne karetopatije vrlo `iv
proces. U ro`ni~noj stromi i endotelu nisu prona|ene zna~ajne razlike u koncentraciji MMP-2, MMP-9, TIMP-1 i
proMMP-13 izme|u KC i BK {to ukazuje da ni jedna od ovih molekula vjerojatno nema zna~ajniju ulogu u patogenezi
ovih oboljenja.
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